LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Lewis, Zawditu"
  2. AU="Wilder, Steven P"
  3. AU="Damnjanovic, Kaja"
  4. AU=Asai Ayumu AU=Asai Ayumu
  5. AU="Tsikouras, Anthony"
  6. AU="Kahn, Mark"
  7. AU="Toegelová, Helena"
  8. AU="Mukhtar Alam"
  9. AU=Krueger Andrew T
  10. AU="Michele Totaro"
  11. AU="Liu, Feiyang"
  12. AU=Mignardi Marco
  13. AU=Yoon Mee-Sup
  14. AU="Schmitt, L."
  15. AU="Clark, Roger"
  16. AU="Tütüncüoğlu, Atacan"
  17. AU=Onuigbo Macaulay Amechi Chukwukadibia
  18. AU="Ohanyerenwa, Chioma"
  19. AU=Kaur Kirandeep
  20. AU=Shrimal Shiteshu
  21. AU=Hamp Thomas
  22. AU="Fazila Aloweni"
  23. AU="Mitchel, Liz"
  24. AU="Aguirre González, Alejandra"
  25. AU="Abdelhak, Bensaid"

Suchergebnis

Treffer 1 - 4 von insgesamt 4

Suchoptionen

  1. Artikel ; Online: IgG Seroconversion and Pathophysiology in Severe Acute Respiratory Syndrome Coronavirus 2 Infection.

    Staines, Henry M / Kirwan, Daniela E / Clark, David J / Adams, Emily R / Augustin, Yolanda / Byrne, Rachel L / Cocozza, Michael / Cubas-Atienzar, Ana I / Cuevas, Luis E / Cusinato, Martina / Davies, Benedict M O / Davis, Mark / Davis, Paul / Duvoix, Annelyse / Eckersley, Nicholas M / Forton, Daniel / Fraser, Alice J / Garrod, Gala / Hadcocks, Linda /
    Hu, Qinxue / Johnson, Michael / Kay, Grant A / Klekotko, Kesja / Lewis, Zawditu / Macallan, Derek C / Mensah-Kane, Josephine / Menzies, Stefanie / Monahan, Irene / Moore, Catherine M / Nebe-von-Caron, Gerhard / Owen, Sophie I / Sainter, Chris / Sall, Amadou A / Schouten, James / Williams, Christopher T / Wilkins, John / Woolston, Kevin / Fitchett, Joseph R A / Krishna, Sanjeev / Planche, Tim

    Emerging infectious diseases

    2020  Band 27, Heft 1

    Abstract: We investigated the dynamics of seroconversion in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. During March 29-May 22, 2020, we collected serum samples and associated clinical data from 177 persons in London, UK, who had SARS- ... ...

    Abstract We investigated the dynamics of seroconversion in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. During March 29-May 22, 2020, we collected serum samples and associated clinical data from 177 persons in London, UK, who had SARS-CoV-2 infection. We measured IgG against SARS-CoV-2 and compared antibody levels with patient outcomes, demographic information, and laboratory characteristics. We found that 2.0%-8.5% of persons did not seroconvert 3-6 weeks after infection. Persons who seroconverted were older, were more likely to have concurrent conditions, and had higher levels of inflammatory markers. Non-White persons had higher antibody concentrations than those who identified as White; these concentrations did not decline during follow-up. Serologic assay results correlated with disease outcome, race, and other risk factors for severe SARS-CoV-2 infection. Serologic assays can be used in surveillance to clarify the duration and protective nature of humoral responses to SARS-CoV-2 infection.
    Mesh-Begriff(e) Adult ; Aged ; Antibodies, Viral/blood ; COVID-19/blood ; COVID-19/immunology ; COVID-19/physiopathology ; Enzyme-Linked Immunosorbent Assay ; Female ; Humans ; Immunoglobulin G/blood ; Male ; Middle Aged ; Reverse Transcriptase Polymerase Chain Reaction ; SARS-CoV-2 ; Seroconversion
    Chemische Substanzen Antibodies, Viral ; Immunoglobulin G
    Sprache Englisch
    Erscheinungsdatum 2020-11-30
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 1380686-5
    ISSN 1080-6059 ; 1080-6040
    ISSN (online) 1080-6059
    ISSN 1080-6040
    DOI 10.3201/eid2701.203074
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  2. Artikel ; Online: Rapid development of COVID-19 rapid diagnostics for low resource settings: accelerating delivery through transparency, responsiveness, and open collaboration

    Adams, Emily R / Augustin, Yolanda / Byrne, Rachel L / Clark, David J / Cocozza, Michael / Cubas-Atienzar, Ana I / Cuevas, Luis E / Cusinato, Martina / Davies, Benedict M. O. / Davies, Mark / Davies, Paul / Duvoix, Annelyse / Eckersley, Nicholas M / Edwards, Thomas / Fletcher, Thomas / Fraser, Alice j / Garrod, Gala / Hadcocks, Linda / Hu, QInxue /
    johnson, Michael / Kay, Grant A / Keymer, Katherin / Kirwan, Daniela / Klekotko, Kesja / Lewis, Zawditu / Mason, Jenifer / Mensah-Kane, Josie / Menzies, Stefanie / Monahan, Irene / Moore, Catherine M / Nebe-von-Caron, Gerhard / Owen, Sophie I / Planche, Tim / Sainter, Chris / Schouten, James / Staines, Henry M / Turtle, Lance / Williams, Chris / Wilkins, John / Woolston, Kevin / Sall, Amadou A / Fitchett, Joseph R.A. / Krishna, Sanjeev

    Abstract: In January, Mologic, embarked on a product development pathway for COVID-19 diagnostics focusing on ELISA and rapid diagnostic tests (RDTs), with anticipated funding from Wellcome Trust and DFID. 755 clinical samples from known COVID-19 patients and ... ...

    Abstract In January, Mologic, embarked on a product development pathway for COVID-19 diagnostics focusing on ELISA and rapid diagnostic tests (RDTs), with anticipated funding from Wellcome Trust and DFID. 755 clinical samples from known COVID-19 patients and hospital negative controls were tested on Mologics IgG ELISA. The reported sensitivity on 191 SGUL prospectively enrolled patients was 95% on day 7 or more post diagnosis, and 97% 10 days or more post-diagnosis. A specificity panel comprising 564 samples pre-December 2019 were tested to include most common respiratory pathogens, other types of coronavirus, and flaviviruses. Specificity in this panel was 97%. This is the first in a series of Mologic products for COVID-19, which will be deployed for COVID-19 diagnosis, contact tracing and sero-epidemiological studies to estimate disease burden and transmission with a focus on ensuring access, affordability, and availability to lowest resource settings.
    Schlagwörter covid19
    Verlag MedRxiv; WHO
    Dokumenttyp Artikel ; Online
    Anmerkung WHO #Covidence: #20082099
    DOI 10.1101/2020.04.29.20082099
    Datenquelle COVID19

    Kategorien

  3. Artikel ; Online: Rapid development of COVID-19 rapid diagnostics for low resource settings: accelerating delivery through transparency, responsiveness, and open collaboration

    Adams, Emily R / Augustin, Yolanda / Byrne, Rachel L / Clark, David J / Cocozza, Michael / Cubas-Atienzar, Ana I / Cuevas, Luis E / Cusinato, Martina / Davies, Benedict M. O. / Davies, Mark / Davies, Paul / Duvoix, Annelyse / Eckersley, Nicholas M / Edwards, Thomas / Fletcher, Thomas / Fraser, Alice j / Garrod, Gala / Hadcocks, Linda / Hu, QInxue /
    johnson, Michael / Kay, Grant A / Keymer, Katherin / Kirwan, Daniela / Klekotko, Kesja / Lewis, Zawditu / Mason, Jenifer / Mensah-Kane, Josie / Menzies, Stefanie / Monahan, Irene / Moore, Catherine M / Nebe-von-Caron, Gerhard / Owen, Sophie I / Planche, Tim / Sainter, Chris / Schouten, James / Staines, Henry M / Turtle, Lance / Williams, Chris / Wilkins, John / Woolston, Kevin / Sall, Amadou A / Fitchett, Joseph R.A. / Krishna, Sanjeev

    medRxiv

    Abstract: In January, Mologic, embarked on a product development pathway for COVID-19 diagnostics focusing on ELISA and rapid diagnostic tests (RDTs), with anticipated funding from Wellcome Trust and DFID. 755 clinical samples from known COVID-19 patients and ... ...

    Abstract In January, Mologic, embarked on a product development pathway for COVID-19 diagnostics focusing on ELISA and rapid diagnostic tests (RDTs), with anticipated funding from Wellcome Trust and DFID. 755 clinical samples from known COVID-19 patients and hospital negative controls were tested on Mologics IgG ELISA. The reported sensitivity on 191 SGUL prospectively enrolled patients was 95% on day 7 or more post diagnosis, and 97% 10 days or more post-diagnosis. A specificity panel comprising 564 samples pre-December 2019 were tested to include most common respiratory pathogens, other types of coronavirus, and flaviviruses. Specificity in this panel was 97%. This is the first in a series of Mologic products for COVID-19, which will be deployed for COVID-19 diagnosis, contact tracing and sero-epidemiological studies to estimate disease burden and transmission with a focus on ensuring access, affordability, and availability to lowest resource settings.
    Schlagwörter covid19
    Sprache Englisch
    Erscheinungsdatum 2020-05-05
    Verlag Cold Spring Harbor Laboratory Press
    Dokumenttyp Artikel ; Online
    DOI 10.1101/2020.04.29.20082099
    Datenquelle COVID19

    Kategorien

  4. Artikel ; Online: Dynamics of IgG seroconversion and pathophysiology of COVID-19 infections

    Staines, Henry M / Kirwan, Daniela E / Clark, David J / Adams, Emily R / Augustin, Yolanda / Byrne, Rachel L / Cocozza, Michael / Cubas-Atienza, Ana I / Cuevas, Luis E / Cusinato, Martina / Davies, Benedict M O / Davis, Mark / Davis, Paul / Duvoix, Annelyse / Eckersley, Nicholas M / Forton, Daniel / Fraser, Alice / Garrod, Gala / Hadcocks, Linda /
    Hu, Qinxue / Johnson, Michael / Kay, Grant A / Klekotko, Kesja / Lewis, Zawditu / Mensah-Kane, Josephine / Menzies, Stefanie / Monahan, Irene / Moore, Catherine / Nebe-von-Caron, Gerhard / Owen, Sophie I / Sainter, Chris / Sall, Amadou A / Schouten, James / Williams, Chris / Wilkins, John / Woolston, Kevin / Fitchett, Joseph R A / Krishna, Sanjeev / Planche, Tim

    medRxiv

    Abstract: We report dynamics of seroconversion to SARS-CoV-2 infections detected by IgG ELISA in 177 individuals diagnosed by RT-PCR. Longitudinal analysis identifies 2-8.5% of individuals who do not seroconvert even weeks after infection. They are younger than ... ...

    Abstract We report dynamics of seroconversion to SARS-CoV-2 infections detected by IgG ELISA in 177 individuals diagnosed by RT-PCR. Longitudinal analysis identifies 2-8.5% of individuals who do not seroconvert even weeks after infection. They are younger than seroconverters who have increased co-morbidity and higher inflammatory markers such as C-Reactive Protein. Higher antibody responses are associated with non-white ethnicity. Antibody responses do not decline during follow up almost to 2 months. Serological assays increase understanding of disease severity. Their application in regular surveillance will clarify the duration and protective nature of humoral responses to SARS-CoV-2.
    Schlagwörter covid19
    Sprache Englisch
    Erscheinungsdatum 2020-06-09
    Verlag Cold Spring Harbor Laboratory Press
    Dokumenttyp Artikel ; Online
    DOI 10.1101/2020.06.07.20124636
    Datenquelle COVID19

    Kategorien

Zum Seitenanfang